BHWM
ACAD icon

Bay Harbor Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bay Harbor Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$228 Hold
9
– – ﹤0.01% 1169
2026
Q1 		$200 Buy
9
+2
+29% +$48 ﹤0.01% 1152
2025
Q4 		$186 Buy
7
+3
+75% +$72 ﹤0.01% 1128
2025
Q3 		$85 Buy
+4
New +$95 ﹤0.01% 1192

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bay Harbor Wealth Management's ACAD Position: Q2 2026 in Review

Bay Harbor Wealth Management held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 9 shares worth $228. The position accounts for ﹤0.01% of the portfolio, ranked #1169.

Bay Harbor Wealth Management first reported a position in ACAD in Q3 2025 and has held it in 4 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Bay Harbor Wealth Management held 9 shares of Acadia Pharmaceuticals worth $228 as of Q2 2026.
  • Bay Harbor Wealth Management left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Bay Harbor Wealth Management's portfolio in Q2 2026, its #1169 holding.
  • Bay Harbor Wealth Management first reported a position in Acadia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Bay Harbor Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.